Liu J-J, Ji S-R, Wu W-H, Zhang Y, Zeng F-Y, Li N-L
Capital Medical University School of Rehabilitation Medicine, China Rehabilitation Research Centre, Beijing, China.
Eur Rev Med Pharmacol Sci. 2014;18(21):3223-8.
This work intended to observe the effect of injecting botolinum toxin type A (BTX-A) for relieving spastic iliopsoas of cerebral palsy on children, and to investigate the improvement of this method for the motor function in these children.
From July 2006 to August 2012, 37 children with spastic iliopsoas cerebral palsy were received rehabilitation therapy. The age ranged from 3 to 15 years. The control group were treated by conventional physical therapy (PY). The experimental group were treated not only by the conventional physical therapy, but also BTX-A injection. The dose of BTX-A injection was according to the weight of the child and the Modified Ashworth Scale (MAS). The dose of the injection ranged from 15 IU to 45 IU with the average dose 31.2±13.9 IU.
There was no significant difference between two the groups on ages, weight and MAS, GMFM (Gross Motor Function Measure) and extension angle of hip joints before treatment. In both groups, the Modified Ashworth Scale decreased, GMFM and extension angle of hip joints increased after eight weeks. In the control group, the GMFM improved significantly. In the experimental group, MAS, GMFM and extension angle of hip joints changed significantly after therapy. There was significant difference between two groups in MAS, GMFM and extension angle of hip joints after two months.
The BTX-A injection can relieve iliopsoas spasticity of cerebral palsy on children efficiently. This therapy can help children to correct abnormal gait and to improve their motor function.
观察注射A型肉毒毒素(BTX-A)缓解小儿脑瘫痉挛性髂腰肌的效果,并探讨该方法对患儿运动功能的改善情况。
2006年7月至2012年8月,37例痉挛性髂腰肌脑瘫患儿接受康复治疗。年龄3至15岁。对照组采用传统物理治疗(PY)。实验组不仅采用传统物理治疗,还进行BTX-A注射。BTX-A注射剂量根据患儿体重和改良Ashworth量表(MAS)确定。注射剂量为15国际单位至45国际单位,平均剂量为31.2±13.9国际单位。
两组患儿治疗前在年龄、体重、MAS、粗大运动功能测量量表(GMFM)及髋关节伸展角度方面无显著差异。两组患儿在治疗8周后,改良Ashworth量表评分均降低,GMFM及髋关节伸展角度均增加。对照组GMFM改善明显。实验组治疗后MAS、GMFM及髋关节伸展角度变化显著。治疗两个月后,两组患儿在MAS、GMFM及髋关节伸展角度方面存在显著差异。
注射BTX-A可有效缓解小儿脑瘫痉挛性髂腰肌。该疗法有助于患儿纠正异常步态,改善运动功能。